Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of the CR Plug (Allograft) for the Treatment of a Cartilage Injury in the Knee.
This study is currently recruiting participants.
Verified by RTI Biologics, September 2009
First Received: November 17, 2008   Last Updated: September 10, 2009   History of Changes
Sponsor: RTI Biologics
Information provided by: RTI Biologics
ClinicalTrials.gov Identifier: NCT00793104
  Purpose

Determine the ability of the allograft plug for the treatment of a cartilage injury in the knee


Condition Intervention Phase
Knee Injury
Procedure: cartilage repair with allograft plug
Phase III

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title: Evaluation of the Composite of Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Focal Cartilage Lesions in the Femoral Condyle

Resource links provided by NLM:


Further study details as provided by RTI Biologics:

Primary Outcome Measures:
  • Decreased in preoperative pain as measured by the KOOS pain subscale [ Time Frame: baseline, 3 months, 6 months, 12 months, 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improvement in quality of life scores, KOOS, improvement in Lysholm with Tegner, IKDC assessment forms, IKDC objective evaluation, MRI results, [ Time Frame: baseline, 3 months, 6 months, 12 months and 24 months, MRI only at 12 and 24 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: November 2008
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: cartilage repair with allograft plug
    Core cartilage defect and implant allograft CR Plug
Detailed Description:

The main objective of this study is to test the ability of an allograft plug to provide successful repair to a cartilage injury in the knee less than 2.5 cm squared.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Skeletally mature
  • Have one symptomatic score ICRS grade 3a, 3b, 3c, 3d, 4a, 4b articular cartilage lesion less than 2.5 cm involving the MFC or LFC. Symptoms must include pain, pain with weight bearing and squatting, locking of joints, and/or swelling
  • Functional meniscal tissue (defined as 5 mm or more width)
  • A score of = or greater than 4 on the VAS questionnaire

Exclusion Criteria:

  • Associated tibial or patellar articular cartilage defect greater than 2 ICRS
  • Osteoarthritis of either knee
  • Mechanical axis malalignment of greater than 5 degrees
  • Patellofemoral incongruity of Merchant view
  • One or more multiple defects greater than 2.5 cm
  • Osteochondritis dissecans (OCD) with depth of bone loss greater than 4 mm
  • Ligament treatments in the affected knee within one yer prior to current study
  • Previous surgical meniscus treatments in the affected knee in the last 6 months
  • Less than 5 mm of meniscal tissue in ipsilateral compartment of study treatment
  • Use of any investigational therapy with in 30 days prior to the first visit
  • Corticosteroid or viscosupplementation within the past 3 months
  • A score of 3 or less on the VAS Questionnaire
  • Active gout or pseudogout or systemic inflammatory condition
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00793104

Locations
United States, California
Kerlan Jobe Orthopaedic Clinic Recruiting
Los Angeles, California, United States, 90045
Contact: Karen Mohr     310-665-7200        
Principal Investigator: Ralph A Gambardella, MD            
United States, Colorado
Colorado Orthopedic Consultants Recruiting
Denver, Colorado, United States, 80012
Contact: Heike Newman     303-695-6060     HeikeNewman@cocortho.com    
Contact: Keiran Browner     303-695-6060        
Principal Investigator: Stewart Weinerman, MD            
United States, Indiana
OrthoIndy, Inc Recruiting
Indianapolis, Indiana, United States, 46237
Contact: Vicki Snodgrass     317-884-5230     vsnodgrass@orthoindy.com    
Principal Investigator: Jack Farr, MD, PhD            
Sponsors and Collaborators
RTI Biologics
Investigators
Principal Investigator: Jack Farr, MD, PhD OrthoIndy, Inc
Principal Investigator: Ralph A Gambardella, MD Kerlan Jobe Orthopaedic Clinic
Principal Investigator: Stewart Weinerman, MD Colorado Orthopedic Consultants
  More Information

Additional Information:
No publications provided

Responsible Party: Regeneration Technologies ( Director of Clinical Projects )
Study ID Numbers: CRP2008, WIRB # 20081109, St Francis IRB Project # 571
Study First Received: November 17, 2008
Last Updated: September 10, 2009
ClinicalTrials.gov Identifier: NCT00793104     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by RTI Biologics:
allograft
knee injury
cartilage injury
Osteochondral defects in the articular femoral cartilage

Additional relevant MeSH terms:
Wounds and Injuries
Disorders of Environmental Origin
Knee Injuries
Leg Injuries

ClinicalTrials.gov processed this record on February 08, 2010